Clinical Trials Search | Clareo Health

Showing 1-2 of 2 trials

Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients

NCT05841342

This prospective case-control study aims to evaluate the immune function and find PD-1 antibody efficacy predictors on Chronic Active Epstein-Barr Virus Infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis by detecting lymphocyte subsets proportions in peripheral blood mononuclear cells and the positive proportion of PD-1, PD-L1 and other indicators in each lymphocyte subsets in healthy people and patients using flow cytometry before and after the initial PD-1 therapy.

Secondary Hemophagocytic LymphohistiocytosisChronic Active Epstein-Barr Virus Infection

Beijing Friendship Hospital128 participantsStarted Oct 2022

Beijing, Beijing Municipality, China

UNKNOWNPhase 3

Rituximab Monotherapy for EBV-HLH and CAEBV

NCT05384743

This study is a prospective single-arm clinical study, focusing on Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection with only and mainly B lymphocytes of EBV infection, to evaluate the clinical efficacy of Rituximab in the treatment of EBV-HLH and CAEBV.

Secondary Hemophagocytic LymphohistiocytosisChronic Active Epstein-Barr Virus Infection

Beijing Friendship Hospital30 participantsStarted Feb 2022

Beijing, China

Data from ClinicalTrials.govTerms

Filters

Filters

Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients

Rituximab Monotherapy for EBV-HLH and CAEBV

Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients

Rituximab Monotherapy for EBV-HLH and CAEBV